Volume | 185,445 |
|
|||||
News | - | ||||||
Day High | 38.00 | Low High |
|||||
Day Low | 37.05 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
37.87 | 37.05 | 38.00 | 37.77 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,691 | 185,445 | $ 37.38 | $ 6,931,415 | - | 22.11 - 53.18 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:24:34 | 200 | $ 37.1281 | USD |
Celldex Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.08B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Celldex Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.87 | 40.45 | 36.78 | 38.71 | 622,509 | -1.74 | -4.48% |
1 Month | 41.33 | 42.38 | 36.78 | 39.89 | 623,212 | -4.20 | -10.17% |
3 Months | 36.02 | 53.18 | 34.65 | 43.32 | 961,337 | 1.11 | 3.08% |
6 Months | 24.44 | 53.18 | 22.11 | 37.81 | 885,402 | 12.69 | 51.92% |
1 Year | 36.51 | 53.18 | 22.11 | 35.64 | 673,891 | 0.6181 | 1.69% |
3 Years | 27.99 | 57.20 | 19.85 | 35.72 | 626,612 | 9.14 | 32.65% |
5 Years | 4.03 | 57.20 | 1.50 | 24.92 | 662,179 | 33.10 | 821.29% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |